Summary by Futu AI
Wuxi Pharmaceutical Ming Kand announced on 11 January 2024 that it has further granted 73,389 shares of H shares to 14 independently selected participants under the H Share Award Trust Scheme 2022, representing approximately 0.018% of the total number of H shares issued and approximately 0.002% of the total issued share capital. This batch of bonus shares was purchased by the Trustee through market transactions as directed by the Company and will not cause dilution to existing shareholders' equity. The award conditions include the Group's full-year revenue growth of no less than 68% in 2022, which has been met. The allocation arrangement of the bonus shares is divided into four stages, calculated from the date on which the selected participant is employed by the relevant member company of the group. The Board considers that this award is in the overall interests of the Company and its shareholders.